<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "journalpublishing3.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="en" article-type="correction">
<?release-delay 0|0?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">OR</journal-id>
<journal-title-group>
<journal-title>Oncology Reports</journal-title>
</journal-title-group>
<issn pub-type="ppub">1021-335X</issn>
<issn pub-type="epub">1791-2431</issn>
<publisher>
<publisher-name>D.A. Spandidos</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3892/or.2026.9061</article-id>
<article-id pub-id-type="publisher-id">OR-55-4-09061</article-id>
<article-categories>
<subj-group>
<subject>Corrigendum</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>[Corrigendum] 3-Bromopyruvate sensitizes human breast cancer cells to TRAIL-induced apoptosis via the phosphorylated AMPK-mediated upregulation of DR5</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author"><name><surname>Chen</surname><given-names>Yuzhong</given-names></name>
</contrib>
<contrib contrib-type="author"><name><surname>Wei</surname><given-names>Li</given-names></name>
</contrib>
<contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Xiaojing</given-names></name>
</contrib>
<contrib contrib-type="author"><name><surname>Liu</surname><given-names>Xianfu</given-names></name>
</contrib>
<contrib contrib-type="author"><name><surname>Chen</surname><given-names>Yansong</given-names></name>
</contrib>
<contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Song</given-names></name>
</contrib>
<contrib contrib-type="author"><name><surname>Zhou</surname><given-names>Lanzhu</given-names></name>
</contrib>
<contrib contrib-type="author"><name><surname>Li</surname><given-names>Qixiang</given-names></name>
</contrib>
<contrib contrib-type="author"><name><surname>Pan</surname><given-names>Qiong</given-names></name>
</contrib>
<contrib contrib-type="author"><name><surname>Zhao</surname><given-names>Surong</given-names></name>
</contrib>
<contrib contrib-type="author"><name><surname>Liu</surname><given-names>Hao</given-names></name>
</contrib>
</contrib-group>
<pub-date pub-type="collection"><month>04</month><year>2026</year></pub-date>
<pub-date pub-type="epub"><day>28</day><month>01</month><year>2026</year></pub-date>
<volume>55</volume>
<issue>4</issue>
<elocation-id>56</elocation-id>
<permissions>
<copyright-statement>Copyright: &#x00A9; 2026 Chen et al.</copyright-statement>
<copyright-year>2026</copyright-year>
<license license-type="open-access">
<license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, reproduction and adaptation in any medium and for any purpose provided that it is properly attributed. For attribution, the original author(s), title, publication source (PeerJ) and either DOI or URL of the article must be cited.</license-p></license>
</permissions>
</article-meta>
</front>
<body>
<p>Oncol Rep 40: <related-article xmlns:xlink="http://www.w3.org/1999/xlink" related-article-type="corrected-article" vol="40" page="2435" id="RA1" xlink:href="10.3892/or.2018.6644" ext-link-type="doi">2435-2444</related-article>, 2018; DOI: 10.3892/or.2018.6644</p>
<p>Following the publication of the above article and a corrigendum (doi: 10.3892/or.2022.8264) that was published 3 years ago to resolve the issue of two sets of duplicated western blots in Fig. 3, an interested reader drew to the authors&#x0027; attention that, in <xref rid="f5-or-55-4-09061" ref-type="fig">Fig. 5b</xref> on p. 2441, the western blot data bands shown to represent the GRP78 and Bcl-2 proteins in the MCF-7 group were strikingly similar; furthermore, the &#x03B2;-actin bands shown for the MDA-MB-231 group in <xref rid="f5-or-55-4-09061" ref-type="fig">Fig. 5c</xref> were strikingly similar to the &#x03B2;-actin bands shown in Fig. 2c on p. 2439.</p>
<p>After having re-examined their original data, the authors realized that the figure parts in question were inadvertently assembled erroneously. The revised version of <xref rid="f5-or-55-4-09061" ref-type="fig">Fig. 5</xref>, now featuring the correct data for the GRP78 western blot bands for the MCF-7 group in <xref rid="f5-or-55-4-09061" ref-type="fig">Fig. 5b</xref> and the &#x03B2;-actin bands in <xref rid="f5-or-55-4-09061" ref-type="fig">Fig. 5c</xref>, is shown in the next page. Note that the errors made in assembling this figure did not affect the overall conclusions reported in the paper. All the authors agree with the publication of this corrigendum, and are grateful to the Editor of <italic>Oncology Reports</italic> for granting them the opportunity to publish this; furthermore, they apologize to the readership for any inconvenience caused.</p>
</body>
<floats-group>
<fig id="f5-or-55-4-09061" position="float">
<label>Figure 5.</label>
<caption><p>AMPK induces ER stress and sensitizes breast cancer cells to TRAIL in response to treatment with 3-BP. (A) Cells treated with medium (Control), 1 &#x03BC;mol/l Compound C (Com C) or Compound C combined with 80 &#x03BC;mol/l 3-BP for 24 h were investigated via flow cytometry. (B) MCF-7 and MDA-MB-231 cells pre-treated with 1 &#x03BC;mol/l Compound C for 1 h were subsequently treated with 0, 40, 80 or 160 &#x03BC;mol/l 3-BP for 24 h. The expression levels of AMPK, GRP78, CHOP and DR5 were investigated with western blotting. (C) Cells pre-treated with or without 1 &#x03BC;mol/l Compound C for 1 h, were treated with medium, Compound C, 80 &#x03BC;mol/l 3-BP, 200 ng/ml TRAIL or both 3-BP and TRAIL, as indicated, for 24 h. The expression levels of Bax and Bcl-2 were determined in MCF-7 cells and caspase-3 was investigated in the MDA-MB-231 cells by western blotting. &#x03B2;-actin served as loading control. TRAIL, tumor necrosis factor-related apoptosis-inducing ligand; 3-BP, 3-bomopyruvate; DR5, death receptor 5.</p></caption>
<alt-text>Figure 5. AMPK induces ER stress and sensitizes breast cancer cells to TRAIL in response to treatment with 3&#x2013;BP. (A) Cells treated with medium (Control), 1 &#x03BC; mol/l Compound C (Com C) or Compound C co...</alt-text>
<graphic xlink:href="or-55-04-09061-g00.jpg"/>
</fig>
</floats-group>
</article>
